O. H. Ng And A. E. EŞKAZAN, "Tackling TKI resistance in AML: A commentary on "Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML." by Yamatani et al.," TRANSLATIONAL ONCOLOGY , vol.19, 2022
Ng, O. H. And EŞKAZAN, A. E. 2022. Tackling TKI resistance in AML: A commentary on "Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML." by Yamatani et al.. TRANSLATIONAL ONCOLOGY , vol.19 .
Ng, O. H., & EŞKAZAN, A. E., (2022). Tackling TKI resistance in AML: A commentary on "Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML." by Yamatani et al.. TRANSLATIONAL ONCOLOGY , vol.19.
Ng, Özden, And AHMET EMRE EŞKAZAN. "Tackling TKI resistance in AML: A commentary on "Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML." by Yamatani et al.," TRANSLATIONAL ONCOLOGY , vol.19, 2022
Ng, Özden H. And EŞKAZAN, AHMET E. . "Tackling TKI resistance in AML: A commentary on "Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML." by Yamatani et al.." TRANSLATIONAL ONCOLOGY , vol.19, 2022
Ng, O. H. And EŞKAZAN, A. E. (2022) . "Tackling TKI resistance in AML: A commentary on "Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML." by Yamatani et al.." TRANSLATIONAL ONCOLOGY , vol.19.
@article{article, author={Özden HATIRNAZ NG And author={AHMET EMRE EŞKAZAN}, title={Tackling TKI resistance in AML: A commentary on "Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML." by Yamatani et al.}, journal={TRANSLATIONAL ONCOLOGY}, year=2022}